Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Harvard Scientific (HVSF)Hot$$- male impotency medicine -- Ignore unavailable to you. Want to Upgrade?

To: Hal who wrote (3541)	5/20/1998 2:35:00 PM
From: Michael Brey	Respond to of 3906

The sad thing is that if they actually were intending on conducting phase II and three testing, they would go broke before they could ever bring the product to market. Hence the need to sucker some large financial backer into this thing. However any large financial backer would have the smarts to do his research on this company and would therefore not touch it with at 10,000ft pole. Only thing this company has is it's patent and I am not so sure how strong that is. You would think that if VVUS thought this company had a snowballs chance, they would buy the patent since it is so much like their product. Sorry for my venting folks, I know I should just shut up and wait for the end like everyone else, but I might as well get some enjoyment out of the money I have lost on this thing. The Company has prepared the protocols for the Phase II study and upon approval from the FDA to proceed with its Phase II clinical trials on the ED product, it can be assumed the Company will experience a significant increase in R&D costs during 1998. In addition, the Company has prepared for the Phase I clinical trials for its psoriasis product and it can be assumed that costs associated with such trials will also contribute to the expected increase in R&D during 1998. Additional R&D costs are expected to be incurred relating to the female dysfunction product, just recently announced by the Company. Such R&D costs are not expected to be as material as costs associated with the ED product and the Psoriasis product, for it is the Company's intention to initially focus on the other two products.